北歐式健走是否可改善帕金森氏症病人的行走能力

The Effectiveness of Nordic Walking in Improving Walking Ability among Patients with Parkinson’s Disease

背景及目的：帕金森氏症病人初期症狀為單側手部靜止性顫抖、動作緩慢及臉部表情減少。隨著病情進展，逐漸出現肌肉僵硬、走路小碎步及平衡感不佳等問題，導致步行困難，增加跌倒風險。過去研究顯示北歐式健走被視為一種具潛力的復健運動，有助於延緩運動症狀並改善非運動症狀進而提高整體生活品質。本文以實證為依據，嚴謹篩選、評讀文獻來探討「北歐式健走是否可改善帕金森氏症病人的行走能力？」的成效。
方法：以PICO擬定關鍵字，運用布林邏輯（OR及AND），搜尋PubMed、Cochrane Library、Ovid MEDLINE、CINAHL及華藝線上圖書館等資料庫，納入截至2025年7月17日前發表的系統性文獻回顧與隨機對照試驗。文獻品質評估採用2024年版CASP評讀工具，證據等級則依據2011年牛津大學實證醫學中心等級表進行判讀，並根據整合結果提出臨床建議。
結果與結論：共納入1篇系統性文獻回顧與統合分析及1篇隨機對照試驗。綜整結果顯示，兩篇研究在方法學上具備一定的嚴謹度。北歐式健走能顯著改善10公尺行走測試與6分鐘步行測試表現；然另一篇隨機對照試驗則顯示，其改善效果與巴西舞蹈、深水運動相比未達統計學顯著差異。綜合文獻證據，北歐式健走是一種簡易、安全且成本較低的運動方式，對改善帕金森氏症病人的行走能力具有潛在效益，但其成效的穩定性仍需更多高品質研究證實。建議可將其作為輔助治療選項之一。

Background and Purpose: Early symptoms of Parkinson’s disease (PD) typically include unilateral resting tremors, bradykinesia, and masked facial expressions. As the disease progresses, patients often develop muscle rigidity, a shuffling gait, and postural instability, significantly increasing the risk of falls and walking difficulties. Existing research suggests that Nordic walking may slow motor progression while improving non-motor symptoms and overall quality of life. This evidence-based project rigorously synthesized literature to evaluate the effectiveness of Nordic walking in improving the walking ability of patients with PD.
Method: Using the PICO framework, a comprehensive search was conducted across major databases using Boolean operators for systematic reviews, meta-analyses, and randomized controlled trials published before July 17, 2025. Literature quality was appraised using the 2024 CASP checklist, and the level of evidence was categorized according to the 2011 Oxford Centre for Evidence-Based Medicine (CEBM) guidelines to formulate clinical recommendations.
Results and Conclusions: The synthesized evidence indicates that while the impact of Nordic walking on walking ability varies across studies, it remains a simple, low-cost, and safe intervention. Implementing Nordic walking can help mitigate the progressive decline in mobility associated with PD and serves as a viable supplementary therapy in clinical practice.